Physician profile
John Patrick Mclaughlin
NPI 1649653353
$742.20
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.41 · 2021: $144 · 2022: $61.55 · 2023: $274 · 2024: $97.90 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.26 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $195.90 | 2022-2025 | Clareon, Argos, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $135.60 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $88.68 | 2021-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $76.99 | 2020-2025 | Veritas Vision System, Tecnis Iol |
| Oyster Point Pharma, INC. | $45.24 | 2023 | Tyrvaya |
| Merz Pharmaceuticals, LLC | $42.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.62 | 2021-2022 | |
| Horizon Therapeutics Plc | $29.45 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $24.54 | 2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Beaver-Visitec International, INC. | $18.66 | 2023 | |
| Amgen INC. | $16.47 | 2025 | Tepezza |
| Allergan, INC. | $14.36 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.